<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00456612</url>
  </required_header>
  <id_info>
    <org_study_id>2006P-000464</org_study_id>
    <nct_id>NCT00456612</nct_id>
  </id_info>
  <brief_title>Radiosurgery for Glioblastoma Multiforme</brief_title>
  <official_title>Phase I/II Study of Fractionated CyberKnife Stereotactic Radiosurgery for High Grade Gliomas in Elderly Patients With Poor Performance Status</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beth Israel Deaconess Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beth Israel Deaconess Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Conventional radiation for 6 weeks is not well tolerated by the elderly. Shorter courses
      (over 3-5 weeks) of radiation have been shown to be equivalent in outcome the elderly-
      particularly in patients who are generally in poor performance status (KPS&lt;70). Fractionated
      Cyberknife Radiosurgery can deliver equivalent doses in 5 treatments providing the same tumor
      control in a much shorter and tolerable schedule improving their quality of their short life.

      To assess the tolerability of Cyberknife Radiosurgery for High Grade Gliomas in Elderly with
      poor performance status.

      Secondary:

      Assessment of local control rate, progression free survival, overall survival, quality of
      life and toxicity and steroid dependence in this population with this regime.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Conventional radiation for 6 weeks is not well tolerated by the elderly. Shorter courses
      (over 3-5 weeks) of radiation have been shown to be equivalent in outcome the elderly-
      particularly in patients who are generally in poor performance status (KPS&lt;70). Fractionated
      Cyberknife Radiosurgery can deliver equivalent doses in 5 treatments providing the same tumor
      control in a much shorter and tolerable schedule improving their quality of their short life.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Poor accrual
  </why_stopped>
  <start_date>February 2007</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Percent Progression -Free Survival at 6 Months Will be Tabulated</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>consent to prgression or death</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response, Median Time to Tumor Progression,Overall Survival, Percent Overall Survival at 1 Year Will be Tabulated.</measure>
    <time_frame>1year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Glioblastoma Multiforme</condition>
  <arm_group>
    <arm_group_label>Cyberknife</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Radiosurgery to enhancing high grade glioma in 5 fractions with escalating doses.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>CyberKnife</intervention_name>
    <description>Radiosurgery to enhancing high grade glioma in 5 fractions with escalating doses.</description>
    <arm_group_label>Cyberknife</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histopathologically confirmed newly diagnosed glioblastoma multiforme or Anaplastic
             Glioma (WHO Grade III) by surgical excision or biopsy.

          2. Patient must recover from the effects of surgery, post-operative infection, or other
             complications.

          3. Therapy should start within 5 weeks of surgery

          4. Must have an estimated survival of &gt; 8 weeks.

          5. KPS &lt; 70.

          6. Age &gt; 65 years.

          7. Must have a pre- and post operative contrast enhanced MRI scans

          8. Laboratory values within the following limits: ANC (absolute neutrophil count) &gt;/=
             1500 cell/ul Platelets &gt;/= 100x 10(3)/ul, Hemoglobin &gt;/= 9g/dl, Serum Creatinine â‰¤
             1.5mg/dl., Serum total Bilirubin &lt;/= 1.5 x upper limit of normal (ULN), SGOT/SGPT &lt;/=
             2.5x ULN, Albumin &gt;/= 3g/dl.

        Exclusion Criteria:

          1. Histology grade less than Anaplastic Glioma ( WHO Grade III).

          2. Recurrent malignant glioma.

          3. Tumor involving the Brain stem.

          4. Any detected tumor foci beyond the cranial vault.

          5. Major medical or psychiatric illness, which in the investigator's opinion will prevent
             administration or completion of the protocol therapy.

          6. Prior malignancies, except for non-melanomatous skin cancers, or carcinoma in situ of
             uterus, cervix or bladder, unless disease free for &gt; 5 years.

          7. Prior chemotherapy for the current disease.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>66 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anand Mahadevan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beth Israel Deaconess Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 4, 2007</study_first_submitted>
  <study_first_submitted_qc>April 4, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 5, 2007</study_first_posted>
  <results_first_submitted>June 22, 2011</results_first_submitted>
  <results_first_submitted_qc>September 3, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 5, 2015</results_first_posted>
  <last_update_submitted>January 23, 2017</last_update_submitted>
  <last_update_submitted_qc>January 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beth Israel Deaconess Medical Center</investigator_affiliation>
    <investigator_full_name>Anand Mahadevan</investigator_full_name>
    <investigator_title>Radiation Oncologist</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Cyberknife</title>
          <description>Radiosurgery to enhancing high grade glioma in 5 fractions with escalating doses.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Single Arm</title>
          <description>Single arm Phase II Study</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Percent Progression -Free Survival at 6 Months Will be Tabulated</title>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cyberknife</title>
            <description>Radiosurgery to enhancing high grade glioma in 5 fractions with escalating doses.
CyberKnife: Radiosurgery to enhancing high grade glioma in 5 fractions with escalating doses.</description>
          </group>
        </group_list>
        <measure>
          <title>The Percent Progression -Free Survival at 6 Months Will be Tabulated</title>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Response, Median Time to Tumor Progression,Overall Survival, Percent Overall Survival at 1 Year Will be Tabulated.</title>
        <time_frame>1year</time_frame>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Progression Free Survival</title>
        <time_frame>consent to prgression or death</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Single Arm</title>
            <description>Single arm Phase II Study</description>
          </group>
        </group_list>
        <measure>
          <title>Progression Free Survival</title>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Single Arm Study</title>
          <description>Single arm Phase II Study</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Early termination due to difficulty in recruitment and retaining due to extremely bad prognosis of disease</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Anand Mahadevan, MD</name_or_title>
      <organization>Beth Israel Deaconess Medical Center</organization>
      <phone>617-667-2345</phone>
      <email>amahadev@bidmc.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

